

Remarks

Claims 1, 3-20, 24-27 and 30 are pending; claims 7, 8, 11 and 17 are withdrawn from consideration. Claim 9 is currently amended.

Rejections under 35 U.S.C. §112

Claim 9 is rejected under 35 U.S.C. §112, second paragraph, as being indefinite. Specifically, the term LABRASOL™ is objected to. Applicant submits that the amendment to claim 9, eliminating the term objected to, renders this objection moot.

Rejections under 35 U.S.C. §103

Claims 1, 3-6, 9-10, 12-16, 18-20, 24-27 and 30 are rejected under 35 U.S.C. §103(a) as being unpatentable over Black et al. (U.S. Patent No. 5,733,909) in view of Sakuma et al. (EP 0695544), Tanida et al. (U.S. Patent No. 6,214,378), and Faour et al. (US 2004/0204413).

Applicant respectfully submits that the Office has not made a prima facie showing of obviousness. As argued in the prior response, dated August 22, 2007, such a showing requires that the cited references describe or suggest every limitation of the claimed invention. None of the cited references describe a dosage form comprising a fill material sealed in capsule shells wherein the fill material comprises celecoxib and sodium metabisulfite, as required by claim 1, and claims dependent therefrom. Thus, the Office has not shown that the pending claims are obvious in view of the cited references.

Conclusion

Applicant believes that the foregoing is a full and complete response to the Office Action of 9/27/2007. Applicant hereby authorizes the Office to credit any overpayment or charge any necessary fees to Deposit Account No. 16-1445.

Respectfully Submitted



Daniel S. Kasten, Reg. No. 45,363

Pfizer, Inc.
P.O. Box 1027
Chesterfield, MO 63006
314-274-5218